Lund Sept 5, 2011
FUJIFILM RI Pharma Co. Ltd (FUJIFILM), owner of the exclusive rights to the Japanese version of EXINI bone™, accelerates the installation rate and has already installed 300 systems in various clinics throughout Japan. The agreement was signed seven months ago.
The customized version of EXINI bone™, referred to as "Bonenavi" in the Japanese market, has been very successful. The extensive installation rate will now also be followed by several publications which confirm the quality and productivity improvement for bone scan images made by EXINI bone.
- "The BSI (Bone Scan Index) values generated by Bonenavi make it possible to get information on whole body and local metastases and are useful to evaluate treatment effect", says Dr. Kenichi Inoue at Saitama Cancer Center, JAPAN
The agreement between EXINI and FUJIFILM was signed in the end of January. In April FUJIFILM had installed 10 systems of EXINI bone. Within mid-June they reached 100 and at the end of August the impressive number of 300 systems has been installed throughout Japan.
- Magnus Aurell, CEO EXINI Diagnostics AB, comments: "The impressive speed of installations is continuing and I’m very glad to note that we, together with FUJIFILM Ri Pharma, manage the support in a very professional and effective way".
For more information, please contact:
Magnus Aurell, CEO
Phone: 046-286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Edenbrandt and currently has 13 employees. EXINI is listed on the stock market square and has about 400 shareholders. Principal owner, Bo Håkansson.
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com, VAT-no: SE556576199501